Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.56 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 3/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | UBE2M | P61081 | 1/20 | 0.49 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3586870 | 0.92 | SIGMAR1 (0.55) | SIGMAR1L3MBTL1TEAD1DRD4KCNH2 | |
| SCHEMBL4305546 | 0.87 | L3MBTL1 (0.64) | SIGMAR1L3MBTL1DRD4KCNH2CXCR3 | |
| SCHEMBL3590338 | 0.87 | SIGMAR1 (0.73) | SIGMAR1TEAD1DRD4LMNA | |
| SCHEMBL27430491 | 0.87 | SIGMAR1 (0.79) | SIGMAR1DRD4CXCR3 | |
| SCHEMBL22233246 | 0.86 | SIGMAR1 (0.61) | SIGMAR1L3MBTL1DRD4CXCR3 | |
| SCHEMBL3935469 | 0.85 | SIGMAR1 (0.67) | SIGMAR1DRD4CXCR3DRD2 | |
| SCHEMBL22716940 | 0.84 | DRD2 (0.66) | SIGMAR1TEAD1DRD4CCR2DRD2 | |
| SCHEMBL3587044 | 0.83 | KCNH2 (0.60) | SIGMAR1L3MBTL1DRD4KCNH2CXCR3 | |
| SCHEMBL29778710 | 0.80 | SIGMAR1 (0.58) | SIGMAR1L3MBTL1DRD4CXCR3OPRM1 | |
| SCHEMBL3596798 | 0.80 | HTR1A (0.63) | SIGMAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | SIGMAR1 2487/4885L3MBTL1 4415/4885TEAD1 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.